Centric Wealth Management Sells 400 Shares of Novo Nordisk A/S (NYSE:NVO)

Centric Wealth Management reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,140 shares of the company’s stock after selling 400 shares during the quarter. Centric Wealth Management’s holdings in Novo Nordisk A/S were worth $528,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. GQG Partners LLC increased its stake in shares of Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after buying an additional 5,556,460 shares during the period. Raymond James Financial Inc. bought a new position in Novo Nordisk A/S during the 4th quarter worth about $404,910,000. Loomis Sayles & Co. L P increased its position in Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock valued at $995,397,000 after purchasing an additional 2,947,771 shares during the period. Clearbridge Investments LLC raised its holdings in shares of Novo Nordisk A/S by 59.8% in the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company’s stock valued at $368,451,000 after purchasing an additional 1,602,549 shares in the last quarter. Finally, Sustainable Growth Advisers LP lifted its position in shares of Novo Nordisk A/S by 23.6% in the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock worth $459,416,000 after purchasing an additional 1,021,498 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 0.4 %

Shares of NYSE:NVO opened at $69.58 on Tuesday. The business’s 50-day moving average is $82.15 and its 200 day moving average is $98.17. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 1 year low of $66.88 and a 1 year high of $148.15. The firm has a market capitalization of $312.24 billion, a P/E ratio of 21.15, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is 47.72%.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.